Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocols

Leukemia

Development of ALL-Hematotox (ALL-HT): Predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia

Blood

Nair MS, Silbert SK, Rejeski K, Wilson KA, Lamble AJ, Valtis YK, Yates B, Morales Arana A, Shouval R, Curran KJ, Gardner RA, Shalabi H, Annesley C, Park JH, Subklewe M, Shah NN

doi: 10.1182/blood.2024025910

Leukemia

Different impacts of granulocyte colony-stimulating factor administration on allogeneic hematopoietic cell transplant outcomes for adult acute myeloid leukemia according to graft type

Am J Hematol

Konuma T, Kameda K, Morita K, Kondo T, Kimura F, Nakasone H, Ouchi F, Uchida N, Tanaka M, Nishida T, Fukuda T, Hasegawa Y, Sakata-Yanagimoto M, Onizuka M, Sawa M, Ota S, Asada N, Fujiwara SI, Yoshihara S, Ishimaru F, Yoshimitsu M, Kanda Y, Ohbiki M, Atsuta Y, Yanada M

doi: 10.1002/ajh.27521

Leukemia

Enhanced Risk Stratification for Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: A Children's Oncology Group Report

Leukemia

DelRocco NJ, Loh ML, Borowitz MJ, Gupta S, Rabin KR, Zweidler-McKay P, Maloney KW, Mattano LA, Larsen E, Angiolillo A, Schore RJ, Burke MJ, Salzer WL, Wood BL, Carroll AJ, Heerema NA, Reshmi SC, Gastier-Foster JM, Harvey R, Chen IM, Roberts KG, Mullighan CG, Willman C, Winick N, Carroll WL, Rau RE, Teachey DT, Hunger SP, Raetz EA, Devidas M, Kairalla JA

doi: 10.1038/s41375-024-02166-1

Leukemia

Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children

N Engl J Med

Gupta S, Rau RE, Kairalla JA, Rabin KR, Wang C, Angiolillo AL, Alexander S, Carroll AJ, Conway S, Gore L, Kirsch I, Kubaney HR, Li AM, McNeer JL, Militano O, Miller TP, Moyer Y, O'Brien MM, Okada M, Reshmi SC, Shago M, Wagner E, Winick N, Wood BL, Haworth-Wright T, Zaman F, Zugmaier G, Zupanec S, Devidas M, Hunger SP, Teachey DT, Raetz EA, Loh ML

doi: 10.1056/NEJMoa2411680

Leukemia

Prognostic relevance of treatment deviations in children with relapsed acute lymphoblastic leukemia who were treated in the ALL-REZ BFM 2002 study

Leukemia

Argyriadi EA, Steffen IG, Chen-Santel C, Lissat A, Attarbaschi A, Bourquin JP, Henze G, von Stackelberg A

doi: 10.1038/s41375-024-02474-6

Leukemia

Comparable relapse incidence after unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide versus conventional anti-graft versus host disease prophylaxis in patients with acute myeloid leukemia: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Am J Hematol

Nagler A, Ngoya M, Galimard JE, Labopin M, Blau IW, Kröger N, Gedde-Dahl T, Schroeder T, Burns D, Salmenniemi U, Rambaldi A, Choi G, Peffault de Latour R, Vydra J, Sengeloev H, Eder M, Mielke S, Forcade E, Kulagin A, Ciceri F, Mohty M

doi: 10.1002/ajh.27383

Leukemia

Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia

Am J Hematol

Othman T, Koller P, Tsai NC, Yang D, Pourhassan H, Agrawal V, Ngo D, Chen J, Farol L, Spielberger R, Sahebi F, Al Malki MM, Cai JL, Sandhu KS, Mansour J, Salhotra A, Ali H, Aribi A, Arslan S, Marcucci G, Forman SJ, Stein AS, Nakamura R, Pullarkat V, Aldoss I, Mei M

doi: 10.1002/ajh.27378

Leukemia

Peripheral blood stem cell versus bone marrow graft for patients ≥60 years undergoing reduced intensity conditioning haploidentical transplantation for acute myeloid leukemia in complete remission: An analysis of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Am J Hematol

Devillier R, Galimard JE, Blaise D, Raiola AM, Bramanti S, Grillo G, Pastano R, de Latour RP, Busca A, López-Corral L, Rodríguez AB, Schmid C, Forcade E, Vydra J, Solano C, Bug G, Neubauer A, Charbonnier A, Brissot E, Nagler A, Ciceri F, Mohty M

doi: 10.1002/ajh.27343

Leukemia

The role of allogeneic stem cell transplantation in acute myeloid leukemia with translocation t(8;16)(p11;p13)

Am J Hematol

Schmälter AK, Labopin M, Versluis J, Gallego Hernanz MP, Eder M, von dem Borne P, Socié G, Chevallier P, Forcade E, Neubauer A, Baron F, Bazarbachi A, Bug G, Nagler A, Schmid C, Esteve J, Mohty M, Ciceri F

doi: 10.1002/ajh.27496

Related content

Development of ALL-Hematotox (ALL-HT): Predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia

Different impacts of granulocyte colony-stimulating factor administration on allogeneic hematopoietic cell transplant outcomes for adult acute myeloid leukemia according to graft type

Enhanced Risk Stratification for Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: A Children's Oncology Group Report

Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children

Prognostic relevance of treatment deviations in children with relapsed acute lymphoblastic leukemia who were treated in the ALL-REZ BFM 2002 study

Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia

The role of allogeneic stem cell transplantation in acute myeloid leukemia with translocation t(8;16)(p11;p13)